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Abstract. 
 
Programmed cell death or apoptosis leads to 
the activation of the caspase-activated DNase (CAD), 
which degrades chromosomal DNA into nucleosomal 
fragments. Biochemical studies revealed that CAD 
forms an inactive heterodimer with the inhibitor of 
caspase-activated DNase (ICAD), or its alternatively 
spliced variant, ICAD-S, in the cytoplasm. It was ini-
tially proposed that proteolytic cleavage of ICAD by 
activated caspases causes the dissociation of the ICAD/
CAD heterodimer and the translocation of active CAD 
into the nucleus in apoptotic cells. Here, we show that 
endogenous and heterologously expressed ICAD and 
CAD reside predominantly in the nucleus in nonapop-
totic cells. Deletional mutagenesis and GFP fusion pro-
teins identiﬁed a bipartite nuclear localization signal 
(NLS) in ICAD and veriﬁed the function of the NLS in 
CAD. The two NLSs have an additive effect on the nu-
clear targeting of the CAD–ICAD complex, whereas 
ICAD-S, lacking its NLS, appears to have a modulatory 
role in the nuclear localization of CAD. Staurosporine-
induced apoptosis evoked the proteolysis and disap-
pearance of endogenous and exogenous ICAD from 
the nuclei of HeLa cells, as monitored by immunoblot-
ting and immunoﬂuorescence microscopy. Similar phe-
nomenon was observed in the caspase-3–deﬁcient 
MCF7 cells upon expressing procaspase-3 transiently. 
We conclude that a complex mechanism, involving the 
recognition of the NLSs of both ICAD and CAD, ac-
counts for the constitutive accumulation of CAD/
ICAD in the nucleus, where caspase-3–dependent regu-
lation of CAD activity takes place.
Key words: apoptosis • chromosomal DNA degrada-
tion • caspase-activated DNase • nuclear targeting • 
caspase-3
 
Introduction
 
Apoptosis is an essential process that controls cell num-
bers during development and participates in the elimina-
tion of cells that have undergone irreparable genomic
damage (Jacobson et al., 1997; Nagata, 1997). Apoptotic
cells show distinctive morphological perturbations, includ-
ing membrane blebbing, cytoskeletal changes, chromatin
condensation, and DNA fragmentation (Jacobson et al.,
1997; Wyllie, 1980). The pathways and the nucleases in-
volved in the progressive destruction of the genomic DNA
have remained elusive until the recent cloning of the het-
erodimeric DNA fragmentation factor (ICAD/CAD or
DFF; Liu et al., 1997; Enari et al., 1998).
The DNA fragmentation factor consists of two subunits,
the 40-kD caspase-3–activated DNase (CAD
 
1
 
 or DFF40)
and the 45-kD inhibitor of CAD (ICAD or DFF45; Liu
et al., 1997, 1998; Enari et al., 1998; Sakahira et al., 1998).
Biochemical isolation of the ICAD–CAD complex from
the cytosolic fraction led to the cloning of the mouse and
human orthologues of ICAD and CAD (Liu et al., 1997,
1998; Enari et al., 1998; Halenbeck et al., 1998). While the
NH
 
2
 
-terminal CIDE-N domain, identified in both ICAD
and CAD, appears to account for heterodimerization (In-
ohara et al., 1998), a putative nuclear localization signal
(NLS) was identified at the COOH terminus of CAD
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The Journal of Cell Biology, Volume 150, 2000 322
 
based on sequence alignment to the SV-40 large T antigen
signal (Enari et al., 1998). CAD is expressed exclusively as
an ICAD/CAD heterodimer, leading to the suggestion
that NLS is masked in nonapoptotic cells (Enari et al.,
1998).
Heterodimerization of ICAD/CAD is obligatory not
only to prevent chromosomal DNA degradation in grow-
ing cells, but also to ensure co- or posttranslational folding
of CAD in the cytoplasm (Liu et al., 1997, 1998; Enari et
al., 1998; Halenbeck et al., 1998; Samejima et al., 1998).
According to this early model, activation of the apop-
totic signaling cascade leads to the proteolysis of ICAD
by effector caspases, permitting the dissociation of the
ICAD–CAD complex, and the subsequent nuclear uptake
of activated CAD (Enari et al., 1998). Besides the full-
length ICAD (or ICAD-L), alternatively spliced variants,
ICAD-S, lacking the last 66 and 62 amino acid residues at
the COOH terminus have been identified in mice and hu-
mans, respectively (Gu et al., 1999; Sakahira et al., 1999).
These ICAD variants can also dimerize with CAD (Gu et al.,
1999), but their function is obscure.
While compelling evidence has characterized the endo-
nuclease activity of mouse CAD (mCAD) and its human
orthologue (hCAD; Enari et al., 1998; Halenbeck et al.,
1998; Inohara et al., 1999; Janicke et al., 1998; Liu et al.,
1998; Mukae et al., 1998; Tang and Kidd, 1998), neither
the colocalization of endogenous ICAD and CAD in the
cytoplasm nor the nuclear translocation of activated CAD
has been demonstrated. However, immunolocalization
data, obtained on cells overexpressing epitope-tagged
hCAD or hICAD, suggested that both ICAD and CAD
are nuclear (Liu et al., 1998). In addition, a fusion protein,
consisting of mICAD and the green fluorescent protein
(GFP), has been found to associate with the nuclei of a va-
riety of transfected cells. Based on these observations, it
was proposed that the nuclear import of GFP-ICAD was
accomplished by association with either CAD or polypep-
tides actively targeted into the nucleus (Samejima and
Earnshaw, 1998). The heterodimerization of ICAD and
CAD was not directly ensured in these experiments, thus,
the controversy regarding the subcellular localization of
the ICAD–CAD complex has remained largely unre-
solved.
To better understand the subcellular compartmentaliza-
tion of the apoptotic DNase, our objectives were to estab-
lish the cellular distribution and to elucidate the targeting
determinants of the CAD–ICAD complex. Immunolocal-
ization of the endogenous ICAD with two polyclonal anti-
bodies provides the direct evidence for the constitutive nu-
clear targeting of ICAD. Using deletional mutagenesis
and fusion proteins, we have identified an NLS at the
COOH terminus of ICAD and confirmed the function of
the NLS of CAD. The two NLSs appear to contribute in
an additive manner to the nuclear targeting of the ICAD–
CAD heterodimer, implying that the caspase-3–dependent
activation of CAD takes place in the nucleus.
 
Materials and Methods
 
Cell Lines and Transfection
 
HeLa, COS-1, MCF7, HTE, PANC, MDCK, CHO, and BHK-21 cells
were grown in 
 
a
 
-modified Eagle’s or DME medium supplemented with
10% FCS at 37
 
8
 
C under an atmosphere of 5% CO
 
2
 
. Transient transfec-
tions were performed with the calcium phosphate precipitation method,
Effecten (QIAGEN), or Fugene (Roche) on 60–70% confluent cells. Cells
were harvested after 48 h of transfection.
To generate HeLa cells stably expressing hICAD-C-myc, cells were
transfected with the pcDNA3-hICAD-C-myc expression vector as cal-
cium phosphate precipitates, and selected in the presence of 0.5 mg/ml
G418 (Geneticin; GIBCO BRL). Clones were screened by indirect immu-
nostaining using the mouse monoclonal anti-myc (9E10, Covance Re-
search Products Inc.) antibody.
 
Plasmid Constructions
 
The cDNA of human ICAD was isolated by PCR cloning, using a cDNA
library prepared from Caco-2 cells (American Type Culture Collection,
accession number HTB37) as a template. The cDNAs encoding the
mCAD and hCAD were provided by Dr. S. Nagata (Osaka University
Medical School, Osaka, Japan) and Dr. R. Halenbeck (Chiron Corp., Em-
eryville, CA), respectively. The membrane-targeted EGFP construct, en-
coding EGFP and the
 
 ras
 
 farnesylation site (EGFPF) and the cDNA of
procaspase-3 were the gift of Dr. W. Jiang (Jiang, 1998) and Dr. V. Dixit,
respectively. Both hICAD and mCAD were subcloned into the expres-
sion plasmid pcDNA3 or into a modified version, incorporating in-frame
fusions of the coding sequences for HA, myc or flag epitopes, at either
the COOH or the NH
 
2 
 
terminus. Deletion mutants ICAD
 
D
 
265-330
(ICAD-S), ICAD
 
D
 
306-331 (ICAD
 
D
 
NLS), mCAD
 
D
 
329-344 (CAD
 
D
 
NLS),
and hCAD
 
D
 
329-338 (hCAD
 
D
 
NLS) were generated by PCR mutagenesis.
cDNA of fusion proteins, comprising EGFP (Cormack et al., 1996) and
the NLS of hICAD (EGFP-ICAD
 
(306-331)
 
 or mCAD (EGFP-CAD
 
(326-344)
 
),
were obtained by inserting the corresponding cDNA fragments (amino
acids 306–331 from ICAD and 326–344 from CAD) into the EcoRI and
ApaI sites of the pEGFP-C1 (CLONTECH Laboratories, Inc.). The plas-
mid encoding GST-hICAD fusion protein was constructed by insertion of
the full-length coding region of hICAD into the EcoRI and XhoI sites of
pGEX-4T1 plasmid. All constructs were verified by dideoxy chain termi-
nation DNA sequencing.
 
Bacterial Expression of hICAD and mCAD
 
To generate polyclonal anti-ICAD antibody, the full-length coding region
of hICAD was fused in-frame with GST in the pGEX-4T1 vector and
transformed in 
 
HB101
 
 bacteria. Production of the fusion protein was in-
duced with 0.1 mM isopropyl 
 
b
 
-
 
D
 
-thiogalactopyranoside. The bacteria sus-
pension was lysed by sonication in 0.5 M NaCl, 20 mM Hepes, 10% glyc-
erol, 0.1 mM EDTA, and 1 mM DTT, pH 7.5. GST-hICAD was purified
from the soluble fraction using glutathione Sepharose 4B (Sigma Chemi-
cal Co.), eluted with sonication buffer supplemented with 10 mM reduced
glutathione, and further purified with SDS-PAGE. Gel slices, containing
GST-hICAD were crushed for immunization of rabbits. Recombinant
hICAD, hICAD-His
 
6
 
, and mCAD-His
 
6
 
 were expressed in BL21(DE3)
cells using the pET15b (Novagen) expression plasmid and purified ac-
cording to the supplier’s recommendations using metal affinity chroma-
tography.
 
Polyclonal Antibody Production
 
Purified GST-hICAD fusion protein was sent to Harlam Bioproducts for
Science for inoculation into rabbits. Immunization was achieved with four
boost of injections (0.5 mg protein/rabbit). The specificity of the rabbit an-
tibodies was determined by comparing the activity of the immune and pre-
immune serum. For immunoblotting and immunofluorescence, the anti-
body was used at 1:1,000–1:3,000 dilution, respectively.
 
Immunofluorescence Microscopy
 
Fluorescence staining of transfected and nontransfected cells was carried
out on glass coverslips after fixing (4% paraformaldehyde for 20 min) and
permeabilizing (0.2% Triton X-100 in PBS for 5 min) the cells as previ-
ously described (Lechardeur et al., 1999). Primary antibodies were as
follows: affinity-purified polyclonal goat anti-ICAD (K-17), anti-myc
(monoclonal and polyclonal; Santa Cruz Biotechnology, Inc.), anti-HA
(monoclonal 16B12; Covance Research Products Inc., and polyclonal,
Santa Cruz Biotechnology, Inc.), and anti-Flag (M2-monoclonal; Sigma
Chemical Co.). Secondary anti-mouse and anti-rabbit antibodies were
conjugated to fluorescein or rhodamine (Jackson ImmunoResearch Labo- 
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ratories). Double immunostaining was performed with pairs of polyclonal
and monoclonal primary antibodies. No significant spillover of the fluo-
rescence signal between the FITC and rhodamine filter sets was detected.
Immunofluorescence micrographs were captured on a Zeiss Axiovert 100
inverted fluorescence microscope (63
 
3
 
/1.4 Planachromat objective) and a
Contax camera as described previously (Lechardeur et al., 1999). Color
slides (1600 ASA Kodachrome) were scanned by a Polaroid slide scanner,
and the images were manipulated with Adobe Photoshop 5.0 software on
a Power Macintosh. Exposure times and background substraction were
held constant for the documentation of the time course of ICAD distribu-
tion. Laser confocal fluorescence microscopy and image processing was
performed using the Zeiss LSM 510 imaging system with Plan neofluor
40
 
3
 
/1.3 objective.
 
Immunoblotting and Coimmunoprecipitation
 
For immunoblottings, cells were washed with ice-cold PBS and lysed in
RIPA buffer (150 mM NaCl, 20 mM Tris-HCl, 1% Triton X-100, 0.1%
SDS, and 0.5% sodium deoxycholate, pH 8.0) containing 10 
 
m
 
g/ml of leu-
peptin and pepstatin, 10 mM iodoacetamide, and 1 mM PMSF for 20 min
at 4
 
8
 
C. Nuclei and unbroken cells were removed by centrifugation (15,000 
 
g
 
for 15 min at 4
 
8
 
C). Soluble proteins were denatured in Laemmli sample
buffer, separated with SDS-PAGE, and transferred to a nitrocellulose
membrane. Immunoblotting, using anti-HA, anti-myc, or anti-hICAD pri-
mary antibodies and enhanced chemiluminescence Western blot kit (Am-
ersham), were performed as previously described (Lukacs et al., 1994).
The CAD-N-HA/ICAD-C-myc heterodimer was isolated with immuno-
precipitation, using anti-HA antibody from cell lysates prepared in TNT
buffer (0.2% Triton X-100, 150 mM NaCl, 20 mM Tris-HCl, pH 7.2). The
immunoprecipitate was separated with SDS-PAGE, transferred to nitro-
cellulose, and detected with anti-myc antibody.
 
Detection of Apoptosis
 
TUNEL assay was performed as previously described (Lechardeur et al.,
1999). Annexin V staining and determination of caspase-3 activity of
HeLa cell extract were carried out with the ApoAlert annexin V and
caspase-3 fluorescent assay kits (CLONTECH Laboratories, Inc.), respec-
tively.
 
Online Supplemental Materials
 
Supplemental Figure 1.  
 
Exogenous hICAD is confined to the nucleus at a
low level of expression. HeLa cells were transiently transfected with
hICAD-C-myc and immunostained with anti-myc and polyclonal anti-
ICAD antibodies. (Available at http://www.jcb.org/cgi/content/full/150/2/
321/DC1.)
 
Supplemental Figure 2.  
 
Expression level of ICAD-S and ICAD-L. (a
and b) The expression level of ICAD-S relative to ICAD-L was deter-
mined with quantitative immunoblotting. (c) The weak cytosolic immu-
nostaining of endogenous ICAD is eliminated in HeLa cells expressing
exogenous mCAD-N-HA, presumably because of the nuclear transloca-
tion of the hICAD-S/mCAD complex. (Available at http://www.jcb.org/
cgi/content/full/150/2/321/DC1.)
 
Supplemental Figure 3.  
 
The NLSs of both hCAD and hICAD contrib-
ute to the nuclear accumulation of the ICAD–CAD complex. Coimmu-
nolocalization of full-length or truncated hCAD-N-HA and hICAD-
C-myc was carried out as depicted on Fig. 7 a. (Available at http://
www.jcb.org/cgi/content/full/150/2/321/DC1.)
 
Supplemental Figure 4.  
 
Distribution of endogenous and exogenous
hICAD in HeLa cells after biochemical fractionation. The ICAD content
of nuclear (nu), microsomal (mi), and cytosolic (cy) fractions of HeLa
cells, obtained by differential centrifugation, were determined with immu-
noblot analysis. (Available at http://www.jcb.org/cgi/content/full/150/2/
321/DC1.)
 
Results
 
Localization of ICAD in Nonapoptotic Cells
 
The subcellular localization of endogenous ICAD was ex-
amined using a polyclonal anti-hICAD antibody, devel-
oped by immunizing rabbits with purified GST-hICAD fu-
sion protein. Western blot analysis showed that the rabbit
anti-hICAD immune serum, but not the preimmune se-
rum, recognizes recombinant hICAD with an apparent
molecular mass of 
 
z
 
45 kD (Fig. 1 a), corresponding to the
predicted molecular mass of hICAD (Liu et al., 1997). No
immuno cross-reactivity was observed with recombinant
mCAD-(His)
 
6
 
 (apparent molecular mass 
 
z
 
40 kD), despite
the presence of the conserved CIDE-N domains in both
CAD and ICAD (Inohara et al., 1998) (Fig. 1 a).
Two major polypeptides were recognized by the anti-
hICAD immune serum, but not by the preimmune serum,
in whole cell lysates of HeLa, COS-1, MCF7, HTE, and
PANC cells, all of human or primate origin (Fig. 1 b). The
slower migrating band, with an apparent molecular mass
of 
 
z
 
45 kD, corresponds to the predicted mass of the full-
length hICAD (ICAD-L). The less abundant polypeptide,
with an apparent molecular mass of 
 
z
 
36 kD, is consistent
in size with the alternatively spliced variant, hICAD-S (Sa-
kahira et al., 1998, 1999; Gu et al., 1999), and was not de-
tected with a polyclonal anti-ICAD antibody, specific for
the COOH terminus of ICAD-L (data not shown). A com-
parable pattern of ICAD expression was revealed with the
affinity-purified goat polyclonal K-17 anti–ICAD anti-
body (Fig. 1 b). Thus, the rabbit and goat anti-hICAD im-
mune serums recognize human ICAD, but cannot recog-
nize hamster (CHO and BHK), mouse (10T), and dog
(MDCK) orthologues (Fig. 1 b).
The subcellular distribution of endogenous hICAD was
established with indirect immunofluorescence microscopy
in five cell lines, including HeLa, HTE, PANC, COS-1,
and MCF7, using two independent anti-ICAD antibodies.
Figure 1. Characterization of the anti-hICAD antibody. (a) The
polyclonal rabbit anti-ICAD immune serum recognizes recombi-
nant hICAD on immunoblot. Full-length hICAD and mCAD-
(His)6 were expressed in BL21(D3) cells, and the bacterial lysates
(z10 mg protein/lanes) were separated with SDS-PAGE, trans-
ferred to nitrocellulose, and polypeptides were visualized by en-
hanced chemiluminescence using rabbit polyclonal anti-hICAD
antiserum (a-ICAD), mouse monoclonal anti-His (a-His) pri-
mary antibody, or preimmune serum with the corresponding
HRP-conjugated secondary antibody. Lysate obtained from
sham-transformed bacteria were used as negative controls. (b)
Western blot analysis of endogenous hICAD expression. Equal
amounts of protein (50 mg) of the indicated cell lysate were sepa-
rated with SDS-PAGE and subjected to immunoblotting as de-
scribed in Materials and Methods. Two prominent immunoreac-
tive polypeptides, with an apparent molecular mass of z45 and
z36 kD, corresponding to the full-length ICAD (ICAD-L) and
the alternatively spliced variant ICAD-S, respectively, are recog-
nized with the rabbit (a-ICAD) and goat (K-17) anti-hICAD an-
tibodies but not with the rabbit preimmune serum (preim). 
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The representative fluorescence micrographs of HeLa and
HTE cells show that hICAD resides predominantly within
the nucleus and is excluded from the nucleolus, with a con-
sistently weak fluorescence signal in cytoplasm (Fig. 2, a
and b). No nuclear staining was detectable with the rabbit
preimmune serum or after the adsorption of the specific
antibody to recombinant ICAD-His
 
6
 
 (Fig. 2 a). Impor-
tantly, the strong nuclear staining of ICAD could be ob-
served with the affinity-purified goat polyclonal anti-
ICAD antibody, as illustrated in the HeLa cells (Fig. 2 c).
These data indicate that hICAD constitutively accumu-
lates in the nucleus in a variety of cells with the mainte-
nance of a reduced level in the cytoplasm.
 
The Nuclear Localization Signal of ICAD
 
The nuclear import ICAD could be achieved passively in
association with CAD or another carrier molecule. Alter-
natively, an unrecognized NLS residing in ICAD could
mediate nuclear uptake. Primary sequence analysis of the
mouse and human ICAD revealed two series of basic resi-
dues separated by a 10–amino acid spacer at the extreme
COOH terminus, which is reminiscent of the consensus se-
quence of the bipartite NLS of nucleoplasmin (Fig. 3 a;
Dingwall et al., 1988; Robbins et al., 1991). Although the
alignment to consensus of the bipartite NLS was less strik-
ing for hICAD, compared with its mouse counterpart,
(Dingwall and Laskey, 1991; Jans and Hubner, 1996; Fig. 3
a), the functional significance of the NLS was tested using
a fusion protein, comprising the enhanced green fluores-
cent protein (EGFP) and the last 26–amino acid residues
of hICAD (EGFP-ICAD
 
306-331
 
). The transiently expressed
EGFP-ICAD
 
306-331
 
 was clearly nuclear (Fig. 3 b, bottom),
in contrast to the EGFP, which was found uniformly dis-
Figure 2. Indirect immunolocalization of endog-
enous hICAD with fluorescence microscopy.
HeLa (a and c) or human tracheal epithelia (b)
cells were fixed, permeabilized, and immu-
nostained with rabbit (a and b) or goat K-17 (c)
polyclonal anti-hICAD primary and tetrameth-
ylrhodamine-conjugated secondary antibody.
Chromosomal DNA was visualized with DAPI
(49,69-diaminidino-2-phenylindole), and identical
fields are shown for hICAD and DNA staining.
Adsorption of the rabbit immune serum to re-
combinant ICAD-His6 prevented the immu-
nostaining of the nuclei (a, blocked). The preim-
mune serum does not recognize any specific
signal (a, preim). Bars: 10 mm. 
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tributed throughout the cells (Fig. 3 b, top). Thus, the
COOH-terminal tail of hICAD is sufficient to confer nu-
clear import capacity to EGFP, and may be implicated in
the nuclear localization of ICAD. During the revision of
this manuscript similar results were reported by Samejina
and Earnshaw (Samejina and Earnshaw, 2000).
Overexpressed hICAD consistently appeared largely
nuclear, with a low level of cytosolic expression in differ-
ent expression systems (HeLa, COS-1, and BHK), regard-
less of the epitope (c-myc, flag, or HA [influenza hemag-
glutinin]) introduced at the COOH or NH
 
2
 
 termini (Fig. 3
c, top and data not shown). Several lines of evidence indi-
cate that NLS-dependent active uptake accounts for the
nuclear localization of overexpressed hICAD. First, the
nuclear accumulation of hICAD was clearly compromised
without NLS. Strong cytosolic immunostaining was de-
tected for hICAD
 
D
 
NLS-C-myc, a recombinant version of
hICAD prepared by deleting the last 26–amino acid resi-
dues, comprising the NLS consensus (Fig. 3 c, bottom).
Further, prominent cytosolic retention was observed for
the epitope-tagged ICAD-S, representing the alternatively
spliced isoform, which lacks the last 66 amino acid residues
(Fig. 3 c, bottom right), suggesting that the nuclear import
of exogenous hICAD cannot be attributed to association
with CAD. Secondly, both stably and transiently trans-
fected hICAD-C-myc was predominantly nuclear at ex-
pression levels, which were comparable to that of endoge-
nous ICAD in HeLa cells (Fig. 4 a, left, and Figure S1
[available at http://www.jcb.org/cgi/content/full/150/2/321/
DC1]). Finally, depletion of the cellular ATP content by
metabolic inhibitors dissipated the nucleocytosolic gra-
dient of hICAD-C-myc (Fig. 4 a, middle), supporting the
hypothesis that nuclear accumulation of hICAD in-
volves active transport. Irreversible deterioration of the
nuclear envelope could not account for this phenome-
non, since hICAD-C-myc reconcentrated in the nuclei
upon the recovery of the cellular ATP content (Fig. 4 a,
right). These observations are consistent with the activ-
ity of a previously unrecognized NLS at the COOH ter-
minus of hICAD. Furthermore, they also suggest that
the weak cytosolic immunostaining, obtained with the
polyclonal anti-ICAD antibodies (Fig. 2), is, most likely,
because of the presence of low levels of monomeric
ICAD-S, confined to the cytoplasm (Figure S2, a and
b  [available at http://www.jcb.org/cgi/content/full/150/2/
321/DC1]). Supporting this notion, the cytosolic immu-
nostaining of ICAD-S was virtually abolished upon tran-
sient expression of CAD-N-HA, with a concomitant in-
crease in the nuclear immunostaining of ICAD (Figure
S2, c).
 
The ICAD/CAD Heterodimer Is Nuclear in 
Nonapoptotic Cells
 
It has been established previously that co- or posttransla-
tional heterodimerization of CAD and ICAD is necessary
for the expression of CAD. The possible impact of het-
erodimerization on the subcellular targeting of ICAD was
assessed by transient coexpression of epitope-tagged hu-
man ICAD and mouse CAD.
Figure 3. Nuclear localization
signals of hICAD. (a) The
COOH-terminal amino acid
residues of the human (h)
and mouse (m) ICAD are
shown aligned. The positively
charged amino acid residues,
representing the putative rec-
ognition signals in the bipar-
tite NLS, are indicated in
bold. (b) The COOH termi-
nus of hICAD directs EGFP
into the nucleus. HeLa cells
were transiently transfected
with the expression plasmid
encoding the EGFP or the
EGFP-ICAD306-331 chimera
and observed with fluores-
cence microscopy. (c) The
COOH terminus confers nu-
clear targeting to hICAD.
HeLa cells were transiently
transfected with the ex-
pression vectors encoding
hICAD-C-myc, hICAD-
N-flag, hICADDNLS-C-myc,
and hICAD-S-C-myc, as in-
dicated. Localization of
ICAD was monitored by in-
direct immunofluorescence
using the corresponding
anti-epitope antibodies. Bars:
10 mm. 
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Three lines of evidence indicated that epitope-tagged
human ICAD, a highly conserved orthologue of mouse
ICAD (Liu et al., 1997; Sakahira et al., 1998), dimerizes ef-
ficiently with mouse CAD. First, physical interaction be-
tween mCAD and hICAD was demonstrated by coim-
munoprecipitation of the hICAD-C-myc/mCAD-N-HA
complex with anti-HA antibody and subsequent immuno-
blotting the precipitate with anti-myc antibody (Fig. 5 a).
Second, the expression level of mCAD-N-HA was sub-
stantially higher (more than sixfold) in the presence of ex-
ogenous hICAD-C-myc, as demonstrated by quantitative
immunoblot analysis (Fig. 5 b, lanes 2 and 3). As a corol-
lary, the level of expression of the exogenous hICAD-
C-myc was significantly higher than that of the endoge-
nous form, which was detected by the rabbit anti-hICAD
antibody (Fig. 5 b, lanes 2 and 3). Finally, the release of
hICAD-C-myc, from the nucleus into the cytosol, was vir-
tually undetectable upon ATP depletion from those nuclei
that expressed both hICAD-C-myc and mCAD-N-HA
(Fig. 4 b), but not hICAD-C-myc alone (Fig. 4 a). This
may be explained by the diffusional barrier of the nuclear
pore complex for polypeptides 
 
.
 
45 kD, such as the
hICAD–mCAD complex (molecular mass 
 
z
 
85 kD; Ding-
wall and Laskey, 1991). Collectively, these experiments in-
dicate that human ICAD can substitute its mouse counter-
part as a chaperone and as an inhibitor of mCAD, as
reported for the heterodimerization of monkey or avian
ICAD with mCAD (Enari et al., 1998; Samejima et al.,
1998). Since similar data were obtained with coexpressing
human CAD and ICAD, we confirmed that expression of
both mCAD and hCAD is strictly limited by the abun-
dance of the endogenous ICAD and increased level of
CAD through heterologous expression can be achieved by
introducing and binding of exogenous ICAD.
The subcellular distribution of hICAD in the ICAD–
CAD complex was investigated by immunofluorescence
staining of HeLa cells, transiently cotransfected with
epitope-tagged hICAD and mCAD. The nearly exclusive
nuclear expression of heterologous hICAD and mCAD
was independent of the epitope (Fig. 6 a), which is consis-
tent with the localization of endogenous hICAD (Fig. 2).
Similar subcellular distribution was observed in COS-1
and BHK cells (data not shown). Association or binding to
nuclear constituents is unlikely to play a major role in the
nuclear retention of ICAD/CAD. In contrast to the nu-
clear proteins, which are resistant to detergent extraction
because of their association with the nucleoskeleton or
chromosomal DNA (e.g., lamina-associated polypeptide
2
 
a
 
, (Lim and Li, 1996)), a low concentration of Triton
X-100 was sufficient to remove both mCAD-N-HA and
hICAD-C-myc from the nucleus (unpublished observa-
tion). As a corollary, monomeric hICAD appears to move
freely in both directions across the nuclear pore complex.
Nuclear accumulation of ICAD/CAD could not be at-
Figure  4. The effect of re-
versible energy depletion on
the distribution of hICAD
and mCAD. ATP depletion
induces the cytosolic release
of overexpressed hICAD in
the absence (a) but not in the
presence of mCAD (b). Indi-
rect immunolocalization of
hICAD and mCAD was car-
ried out on HeLa cells stably
expressing hICAD-C-myc
(hICAD) (a), or transiently
overtransfected with mCAD-
N-HA (b, hICAD 1 mCAD).
The epitopes were visualized
as described in Materials and
Methods. ATP depletion was
achieved by incubating the
cells in the presence of meta-
bolic inhibitors (4 mg/ml
antimycin A, 10 mM deoxy-
D-glucose, and 10 mM car-
bonyl cyanide p-chlorophenyl
hydrazone; ATP-depletion)
for 2 h at 378C. ATP reple-
tion was attained by exten-
sive rinses and incubating the
cells in normal medium for
3 h (ATP-repletion). Export
of ICAD from the nuclei into
the cytoplasm upon ATP de-
pletion is evident in cells
without mCAD expression
(arrowheads). Bars: 10 mm. 
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tributed to activation of apoptosis, since neither increased
chromosomal DNA fragmentation nor phosphatidylserine
translocation into the outer leaflet of the plasma mem-
brane was detectable by terminal deoxynucleotidyl trans-
ferase–mediated dUTP nick end-labeling (TUNEL) assay
or annexin V staining, respectively. Finally, identical local-
ization was demonstrated for the epitope-tagged hICAD/
hCAD heterodimer (Fig. 6 b), supporting our hypothesis
that nuclear targeting of ICAD/CAD is an inherent char-
acteristic of the complex, rather than the consequence of
heterologous expression, and dimerization ICAD does not
impair its nuclear accumulation.
 
The Role of ICAD in the Nuclear Targeting of the 
ICAD–CAD Complex
 
Polypeptides 
 
.
 
45 kD require an NLS and interactions
with nuclear transport receptors to be targeted specifically
into the nucleus (Kalderon et al., 1984; Newmeyer and
Forbes, 1988; Dingwall and Laskey, 1991). It is possible
that nuclear accumulation of the ICAD–CAD complex,
with a molecular mass of 
 
z
 
85 kD, relies on either or both
of the NLS motifs of its constituents. Given that the heter-
ologously expressed ICAD–CAD complex is largely com-
prised of epitope-tagged components, the individual con-
tribution of NLS of CAD and ICAD could be elucidated.
The subcellular distribution of the ICAD–CAD complex
was scored on the basis of the nucleocytoplasmic gradient
of mCAD, since heterodimerization is obligatory for the
expression of CAD (Enari et al., 1998; Halenbeck et al.,
1998; Liu et al., 1998; Inohara et al., 1999). Data in the pre-
vious section and analysis of 
 
.
 
400 transfected cells
showed that hICAD–mCAD complex is essentially nu-
clear (Fig. 6 and Fig. 7, a and b, filled bars). In contrast,
deletion of the ICAD NLS impeded the nuclear import
of the complex, reflected by the cytosolic localization
Figure 5. Expression and interaction of mCAD with hICAD. (a)
hICAD associates with mCAD. HeLa cells were transiently
transfected with hICAD-C-myc and mCAD-N-HA expression
constructs. Immunoprecipitation of the ICAD–CAD complex
was performed with monoclonal mouse anti-HA antibody.
Whole cell lysates and immunoprecipitate (IP) were separated
with SDS-PAGE and probed with anti-myc antibody. (b) Heter-
ologous expression of mCAD-N-HA is limited by the endoge-
nous hICAD. HeLa cells were transiently transfected with the
plasmid encoding the indicated constructs and carrier DNA
(pcDNA3). 2 d after transfection, cells were lysed and equal
amounts of protein (50 mg) were separated with SDS-PAGE and
transferred to nitrocellulose. Polypeptides were visualized with
enhanced chemiluminescence using anti-HA (a-HA), anti-myc
(a-myc), or anti-ICAD antibodies.
Figure 6. Colocalization of epitope-tagged CAD and ICAD. (a) Nuclear colocalization of epitope-tagged hICAD and mCAD and (b)
hICAD and hCAD. HeLa cells were transiently transfected with the expression vectors encoding mCAD or hCAD with the indicated
epitope. Immunostaining was performed with a combination of rabbit polyclonal anti-HA and mouse monoclonal anti-Flag or anti-myc
antibodies, and the corresponding fluorescein- and rhodamine-conjugated secondary antibodies and were detected by fluorescence mi-
croscopy. Identical fields are shown for ICAD and CAD distribution. Bars: 10 mm. 
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of mCAD-N-HA and hICAD
 
D
 
NLS-C-myc heterodimer
(Fig. 7 a). Similar subcellular distribution of mCAD was
observed in the presence of ICAD-S-C-myc (Fig. 7 a), sug-
gesting that the NLS of hICAD is necessary for the effi-
cient nuclear accumulation of the CAD–ICAD complex.
Furthermore, these results also imply that nuclear uptake
of CAD may be influenced by the expression level of
ICAD-S. This latter possibility was verified by determin-
ing the subcellular distribution of mCAD in complex with
hICAD-S. Nuclear accumulation of mCAD was observed
only in 52% of the expressors and showed substantial cy-
tosolic staining in the rest of the transfectants upon coex-
pression with hICAD-S (Fig. 7 c, empty bars).
The possibility that hICAD
 
D
 
NLS or hICAD-S is unable
to chaperone the folding of mCAD, leading to a nonna-
tive, and perhaps mistargeted mCAD seems unlikely since
the expression level of mCAD was augmented by either
the full-length or truncated variants of hICAD more than
Figure 7. The NLSs of both
mCAD and hICAD contrib-
ute to the nuclear accumula-
tion of the ICAD–CAD com-
plex. Coimmunolocalization
of full-length or truncated
mCAD-N-HA and hICAD-
C-myc was carried out as on
Fig. 6. (a) HeLa cells were
cotransfected with the indi-
cated expression constructs
encoding for the full-length
or truncated mCAD-N-HA
and hICAD-C-myc and visu-
alized by indirect immu-
nostaining. Identical fields are
shown for ICAD (red) and
CAD (green) staining. (b and
c) Estimation of the nucleo-
cytoplasmic concentration
gradient of the exogenous
ICAD–CAD complex, based
on the subcellular distribu-
tion of mCAD-N-HA or
mCADDNLS-N-HA in the
presence of hICAD-C-myc
or hICAD-S-C-myc. Accord-
ing to the nucleocytoplasmic
concentration gradient of
CAD-N-HA or CADDNLS-
N-HA, the distribution pat-
tern of transfected cells was
classified into four groups: (1) mCAD was exclusively nuclear (nuclear); (2) mCAD concentration was higher in the nucleus than in cy-
toplasm; (3) no significant concentration difference could be recognized between the nucleus and the cytoplasm; and (4) the concentra-
tion of mCAD in the cytoplasm was higher than in the nucleus. The composition of the exogenous ICAD–CAD complex is indicated on
the right: wt, mCAD-N-HA or hICAD-C-myc; DNLS, mCADDNLS-N-HA; and S, hICAD-S-C-myc. For each transfection, .400 cells
were scored in two to three independent experiments. Bar, 10 mm.  
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six-fold, as measured by quantitative immunoblot analysis
(Fig. 8 a, lanes 1–4). Similar distribution patterns were ob-
served when human CAD-N-HA was coexpressed with
the full-length or truncated hICADs (Figure S3 [avail-
able at http://www.jcb.org/cgi/content/full/150/2/321/DC1]),
precluding the possibility that dimerization of hICAD with
mCAD induced the exposure of a buried NLS. Hence, we
conclude that the NLS of hICAD has an important role in
the constitutive nuclear localization of the ICAD/CAD
heterodimer.
 
The Role of CAD in the Nuclear Targeting of the 
ICAD–CAD Complex
 
To examine the possible role of CAD in the nuclear tar-
geting of the ICAD–CAD complex, the function of its pu-
tative NLS was also evaluated. The COOH-terminal tail of
mCAD, containing the positively charged amino acid clus-
ter (
 
326
 
RRKQPARKKRPARKR
 
344
 
), was fused in-frame
to EGFP. The transiently expressed EGFP-CAD
 
326-344
 
 chi-
meric polypeptide was nuclear in HeLa cells, indicating
that the COOH terminus of mCAD is sufficient to confer
nuclear import capacity to EGFP (Fig. 8 b).
The significance of the NLS in the context of mCAD was
demonstrated by immunolocalization of the COOH termi-
nally truncated mCAD lacking its NLS (CADDNLS). De-
letion of the NLS disrupted the nuclear import of the
CADDNLS-N-HA as well as the coexpressed ICAD-
C-myc (Fig. 7 a). In contrast to the exclusive nuclear local-
ization of mCAD and hICAD (Figs. 6 and 7, a and b,
filled bar), the complex comprising the mCADDNLS and
hICAD remained cytosolic for .50% of the transfectants
(Fig. 7 c, filled bar). The rest of the transfectants displayed
incomplete nuclear accumulation with significant amount
of cytosolic mCADDNLS-NHA (Fig. 7 c). Importantly, de-
letion of the NLS in mCAD does not seem to interfere with
its biosynthesis and folding, since the expression level of
mCADDNLS was comparable to that of mCAD, in the
presence of either the full-length or the truncated hICADs
(Fig. 8 a, lanes 6–8). Furthermore, deletion of the putative
NLS of the human CAD caused a similar subcellular distri-
bution of the ICAD–CADDNLS complex (Figure S3).
Thus, perturbation of the nuclear localization of the ICAD/
CAD heterodimer by CADDNLS provides direct evidence
for the role of CAD NLS. Therefore, we conclude that
NLSs of both ICAD and CAD contribute to the constitu-
tive nuclear import of the complex. Our results also imply
that translocation of activated CAD from the cytoplasm
into the nucleus is not occurring specifically to achieve
fragmentation of chromosomal DNA during apoptosis.
The NLSs of ICAD and CAD Contribute to the 
Nuclear Uptake of ICAD–CAD Complex in an 
Additive Manner
To assess whether the NLS of each constituent partici-
pates in the nuclear targeting of the ICAD–CAD complex,
the subcellular distribution of the heterodimer composed
of mCADDNLS and ICADDNLS was examined. In strik-
ing contrast to the nuclear colocalization of mCAD-N-HA
and hICAD-C-myc (Fig. 9 a), the nuclear targeting of the
complex lacking both NLSs was virtually abolished, as il-
lustrated by the laser confocal fluorescent micrographs
(Fig. 9 b). Comparable results were obtained with the
mCADDNLS-N-HA/hICAD-S-C-myc complex (Fig. 7
a). Nuclear accumulation of the mCADDNLS-N-HA/
hICAD-S-C-myc complex could not be recognized in 81%
of the transfected cells, and appeared to be excluded from
the nucleus in 19% of the expressors (Fig. 7 b, empty bar).
Since the cytosolic expression of the ICAD/CAD was sub-
stantially more pronounced when both NLSs were absent,
in contrast to single NLS deletion, we conclude that the
NLSs of both ICAD and CAD are required for efficient
nuclear import of the heterodimer.
Figure 8. The importance of the NLS of CAD in its expression
and nuclear targeting. (a) Heterologous expression of mCAD
and mCADDNLS requires the presence of either the full-length
or the truncated variant of hICAD. The expression of mCAD-
N-HA or mCADDNLS-N-HA was determined in the absence or
presence of hICAD-C-myc (L), hICAD-S-C-myc (S), or
hICADDNLS-C-myc (DN) in transiently transfected HeLa cells,
using anti-HA antibody. The expression of ICAD was visualized
with anti-myc antibody. (b) The COOH terminus of mCAD di-
rects EGFP into the nucleus. HeLa cells were transiently trans-
fected with the expression vector encoding EGFP or EGFP-
CAD326-344 fusion, comprising the putative NLS of mCAD and
observed with fluorescence microscopy. Bar, 10 mm.The Journal of Cell Biology, Volume 150, 2000 330
Staurosporine-induced Apoptosis Is Associated with the 
Caspase-dependent Release of ICAD from the Nucleus
Immunolocalization of endogenous hICAD suggests that
proteolytic activation of ICAD/CAD takes place in the
nucleus, rather than in the cytoplasm as proposed previ-
ously (Enari et al., 1998). To test this prediction, the cellu-
lar distribution of endogenous and epitope-tagged hICAD
was monitored upon staurosporine-induced apoptosis. Ac-
cording to the immunostaining, staurosporine evoked a
time-dependent disappearance of hICAD from the nuclei
of HeLa cells. The nuclear expression of the endogenous
hICAD appears to be abolished in most of the cells after
3 h of incubation with staurosporine (Fig. 10 a). Nearly
complete elimination of the fluorescence signal derived
from the exogenous ICAD-C-myc was observed after 2 h
of incubation with staurosporine (Fig. 10 b). The more
pronounced diminution of the ICAD-C-myc could be
attributed to an increased caspase susceptibility of the
monomeric hICAD-C-myc, and/or the small size of c-myc
epitope, as compared with multiple epitopes detected with
the polyclonal anti-ICAD antibody.
In sharp contrast to HeLa cells, the nuclear expression
of the endogenous hICAD was preserved upon staurospo-
rine treatment of MCF7 cells, a cell line which lacks func-
tional caspase-3 (Janicke et al., 1998; Fig. 10 c). Consistent
with the immunostaining results, a significant decrease in
the total cellular pool of hICAD (and ICAD-S) was docu-
mented with immunoblot analysis of HeLa, but not MCF7
cells, upon induction of apoptosis with staurosporine (Fig.
10, d–e). The effect of staurosporine on ICAD degrada-
tion was sensitive to DEVD-CHO, an inhibitor of caspases-3,
-6, and -7 (data not shown).
The lack of a staurosporine effect on the degradation of
ICAD in MCF7 cells could not be explained by the ab-
sence of the upstream apoptotic signaling cascade, since
hICAD could be eliminated from the nuclei after the com-
plementation of the cells with procaspase-3. MCF7 cells
were cotransfected with plasmids encoding procaspase-3
and membrane-targeted EGFP (EGFPF) at a molar ratio
of 4:1. The inclusion of EGFPF facilitated the identifica-
tion of procaspase-3 expressors. Activation of procaspase-3
with staurosporine caused the disappearance of endoge-
nous ICAD from the nuclei of MCF7 cells expressing both
EGFPF and caspase-3, but not EGFPF alone, as detected
with immunostaining (Fig. 11). These in situ immunolo-
calization studies suggest that expression of caspase-3 is
indispensable for proteolytic activation of ICAD/CAD,
which takes place in the nucleus.
Discussion
Based on in vitro reconstitution of chromosomal DNA
degradation, it was initially postulated that proteolytic
cleavage of ICAD by caspase(s) would allow the dissocia-
tion of ICAD from CAD in the cytosol and unmasking the
NLS of CAD, permitting the nuclear import of the active
nuclease (Enari et al., 1998). However, recent reports
of the nuclear localization of heterologously expressed
epitope-tagged hICAD and GFP-mICAD fusion proteins
were inconsistent with this activation mechanism, and sug-
Figure 9. Coimmunolocaliza-
tion of wt- and NLS-deficient
ICAD and CAD with laser
confocal microscopy. (a)
Immunofluorescence detec-
tion of mCAD-N-HA and
hICAD-C-myc in transiently
transfected HeLa cells using
anti-HA and anti-myc anti-
bodies. mCAD and hICAD
colocalize throughout the nu-
cleus. (b) Deletion of the
NLSs results in cytosolic lo-
calization of the exogenous
ICAD–CAD complex. Im-
munofluorescence detection
of overexpressed mCADD-
NLS-N-HA and hICADD-
NLS-C-myc in transiently
transfected HeLa cells using
anti-HA and anti-myc anti-
bodies. Bars: 10 mm.Lechardeur et al. Nuclear Targeting of the ICAD/CAD Heterodimer 331
Figure  10. The effect of
staurosporine on the local-
ization and expression of
hICAD. The subcellular
distribution of endogenous
hICAD (a and c) and
transiently overexpressed
hICAD-C-myc (b) were vi-
sualized in HeLa (a and b)
and MCF7 (c) cells before
and after staurosporine (2
mM) treatment for 2 h at
378C. Cells were fixed, per-
meabilized, and hICAD and
hICAD-C-myc were im-
munostained with the rabbit
polyclonal anti-hICAD
(a-ICAD) and anti-myc an-
tibodies, respectively. Chro-
mosomal DNA was visual-
ized with DAPI, and
identical fields are shown for
hICAD and DNA staining.
(d and e) The effect of stau-
rosporine on the expression
level of hICAD. HeLa (d)
and MCF7 (e) cells were in-
cubated in the presence of 2
mM staurosporine for the in-
dicated time. Cellular pro-
teins were solubilized in
RIPA buffer, and equal
amounts of protein (50 mg)
were analyzed by immuno-
blotting using polyclonal
rabbit (a-ICAD) and goat
(K-17) anti-hICAD antibod-
ies. Bars: 10 mm.The Journal of Cell Biology, Volume 150, 2000 332
gested that ICAD may play a direct role in the nuclear tar-
geting of CAD in nonapoptotic cells (Liu et al., 1998;
Samejima and Earnshaw, 1998). To resolve these conflict-
ing observations and establish the mechanism of ICAD’s
action, immunolocalization of endogenous and heterolo-
gously expressed ICAD was performed in growing and
apoptotic cells. Our results offer direct evidence for the
constitutive nuclear targeting of the ICAD–CAD complex
in nonapoptotic cells and document the caspase-3–depen-
dent proteolytic cleavage of ICAD in the nucleus.
A number of observations indicate that the ICAD/CAD
heterodimer resides, predominantly, in the nucleus of non-
apoptotic cells. A panel of epitope-tagged ICAD and
CAD variants was expressed in combinations or individ-
ually to demonstrate that they localize and colocalize in
the nucleus. Nuclear localization was independent of the
expression system or the epitope employed, and did not
coincide with either DNA fragmentation or phosphati-
dylserine translocation (Figs. 4, 6, and 9). Moreover, inhibi-
tion of caspase activity with DEVD-CHO had no effect on
the nuclear localization of exogenous ICAD/CAD or en-
dogenous ICAD (data not shown). Finally and most im-
portantly, we have demonstrated that endogenous hICAD
is predominantly confined to the nucleus in diverse cell
types with two independent polyclonal anti-hICAD anti-
bodies (Fig. 2). Although we were unable to determine the
subcellular localization of endogenous CAD, given the
obligatory heterodimerization of the inactive CAD with
ICAD, these experiments strongly suggest that the ICAD–
CAD complex is targeted constitutively into the nucleus.
One of the most important findings of our study is the
elucidation of the nuclear targeting signals of the ICAD–
CAD complex. These experiments relied on the observation
that coexpression of hICAD ensured a dramatic increase
in the level of heterologous CAD, enabling investigations
of the role of the NLSs without significant interference
from the endogenous ICAD/CAD. In addition to identify-
ing the NLS of ICAD, we have functionally verified the
NLS in both mCAD and hCAD using two criteria. First,
the NLSs of mCAD and hICAD were transferable. Both
EGFP-ICAD306-331 and EGFP-CAD326-344 chimeras were
targeted to the nucleus, in contrast to the homogenous cel-
lular distribution of the EGFP (Figs. 3 b and 8 b). Second,
the deletion of the bipartite NLS from the COOH termi-
nus of hICAD manifested in the cytosolic accumulation of
monomeric hICAD-S-C-myc and hICADDNLS-C-myc as
opposed to the full-length ICAD, which was predomi-
nantly nuclear (Fig. 3 c).
The role of the NLS of CAD was assessed in cells
cotransfected with hICAD and truncated CAD. Incorpo-
ration of mCADDNLS, or hCADDNLS into the het-
erodimer partially disrupted its nuclear accumulation, sim-
ilar to that observed in the presence of hICADDNLS,
implying that the NLS of CAD is also recognized by the
Figure 11. The effect of staurosporine-induced apoptosis on the localization of hICAD in MCF7 cells. MCF7 cells were transiently
transfected with plasmids encoding for (top) EGFPF and pcDNA3 or (bottom) procaspase-3 and EGFPF at a molar ration of 4:1. Im-
munostaining of endogenous hICAD was performed with rabbit anti-ICAD immune serum after exposing the cells to staurosporine (2
mM) for 2 h at 378C and visualized with laser confocal microscopy. The arrowheads indicate those nuclei that have lost ICAD expres-
sion. Bar, 10 mm.Lechardeur et al. Nuclear Targeting of the ICAD/CAD Heterodimer 333
nuclear import machinery in the complex. Importantly,
when the NLSs of both ICAD and CAD were deleted,
the nuclear exclusion of mCADDNLS/hICAD-S and
mCADDNLS/hICADDNLS became obvious (Fig. 9). The
more pronounced cytosolic accumulation of the double
mutants relative to that of single NLS deletion suggests
that the two NLSs have an additive effect on the nuclear
targeting efficiency of the ICAD–CAD complex. A cumu-
lative effect of multiple nuclear localization signals on the
targeting of soluble polypeptides is not without precedent.
A number of proteins harbor two or more NLSs (e.g., c-myc,
Mata2, and p53), which are required to achieve complete
nuclear localization. Multiple copies of NLS apparently
ensure more efficient targeting than do single copies
(Dworetzky et al., 1988; Jans and Hubner, 1996). The
unique feature of ICAD/CAD targeting is that the two
NLSs reside within distinct components of the complex.
In the light of the nuclear localization of the ICAD–
CAD complex, it is reasonable to assume that the DNA
fragmentation activity, which was isolated from the cytosol
of apoptotic cells, was released from the nucleus during
the preparation procedure, when ATP-dependent nuclear
import was mitigated (Mitamura et al., 1998; Sabol et al.,
1998). Perturbing the integrity of the nuclear envelope may
have contributed to the cytosolic appearance of the ICAD–
CAD complex during biochemical purification (Enari et al.,
1998; Mitamura et al., 1998; Sabol et al., 1998). This spec-
ulation is supported by the findings that comparable
amounts of ICAD and ICAD-C-myc/CAD-N-HA were
associated with the nuclear and cytosolic fractions of
HeLa cells, regardless of the homogenization technique
used (nitrogen cavitation or freeze-thaw method, Figure
S4 [available at http://www.jcb.org/cgi/content/full/150/2/
321/DC1]). Furthermore, rapid loss of the exogenous
ICAD–CAD complex was detected from the nuclei of
NIH3T3 cell during digitonin fractionation (Dr. Robert
Halenbeck, personal communication). These observa-
tions are in sharp contrast with the exclusive nuclear local-
ization of the ICAD-C-myc/CAD-N-HA complex, as
demonstrated by immunostaining, but are in line with pre-
vious reports documenting the loss of nuclear proteins
during subcellular fractionation (Liu et al., 1998; Pain et al.,
1983).
Activation of the ICAD/CAD Heterodimer Occurs in 
the Nucleus
The constitutive nuclear accumulation of ICAD/CAD
dimer implies that regulation of CAD activity, most likely,
takes place in the nucleus. How nuclear ICAD/CAD is ac-
tivated upon apoptosis is an important question in under-
standing the mechanism of chromosomal DNA degrada-
tion. Convincing in vivo and in vitro data demonstrate that
activation of CAD requires the proteolytic cleavage of
ICAD by the caspase cysteine proteases (Mitamura et al.,
1998; Sabol et al., 1998; Samejima et al., 1998; Tang and
Kidd, 1998; Sakahira et al., 1999). Our results provide
some insights into this process in situ. Progressive disap-
pearance of both the endogenous and the heterologously
expressed hICAD was observed upon staurosporine-
induced apoptosis from the nuclei of HeLa cells (Fig. 10).
In contrast, staurosporine failed to promote ICAD degra-
dation in caspase-3–deficient MCF7 cells, unless these
cells were transiently transfected with the expression plas-
mid encoding procaspase-3 (Figs. 10 and 11), underlining
the central role of caspase-3 in the regulation of CAD ac-
tivity (Enari et al., 1998; Liu et al., 1998).
In the absence of evidence for the constitutive recycling
of ICAD/CAD between the cytoplasm and the nucleus, the
apoptotic signaling cascade must either trigger nuclear up-
take of the heterotetrameric, activated caspase-3 or acti-
vate procaspase-3 within the nucleus to direct the pro-
teolytic cleavage of the heterodimeric ICAD. While we are
unable to distinguish between these possibilities at the
present time, circumstantial and direct evidence suggest
that nuclear translocation of both procaspases and active
caspases can occur. Immunolocalization experiments have
convincingly shown the nuclear import of caspase-9 in
apoptotic neurons and suggested a similar process for
caspase-3 in neuroblastoma cells (Nakagawara et al., 1997;
Krajewski et al., 1999). Degradation of several caspase
substrates, such as lamins, gelsolin, poly(ADP-ribose)
polymerase, DNA-dependent protein kinase, and NUP153,
is confined to the nucleus (Lazebnik et al., 1994, 1995;
Zheng et al., 1998; Buendia et al., 1999), implying that ac-
tive caspases are present in the apoptotic nucleus. Finally,
nuclear localization signals were revealed in the pro-
domain of caspase-1 and caspase-2, which appear to be re-
quired for the nuclear targeting (Colussi et al., 1998; Mao
et al., 1998).
What are the biological advantages of the constitutive
accumulation of ICAD/CAD in the nucleus? First, pro-
grammed cell death is often associated with a loss of mito-
chondrial membrane potential and impaired ATP produc-
tion by the respiratory chain (Green and Reed, 1998),
which would be anticipated to compromise active nuclear
import. Nuclear residence of ICAD/CAD renders the
ATP-dependent nuclear import of CAD unnecessary in
apoptotic cells. Second, since dimer formation is a prereq-
uisite for the efficient nuclear targeting of CAD, this
mechanism may play a role in ensuring that CAD remains
enzymatically inactive in the nuclei of growing cells. On
the other hand, the proximity of the DNase substrate
would readily facilitate the cleavage of chromosomal DNA
when the apoptotic enzyme cascade is activated. Finally,
the nuclear targeting of ICAD/CAD may provide an addi-
tional mechanism for modulating the apoptotic tendency
of nuclei. Since alterations in the ratio of ICAD-S/ICAD
have been documented (Sabol et al., 1998), and ICAD-S
appears to impair nuclear targeting of the heterodimer, as
demonstrated by the cytosolic accumulation of ICAD-
S–CAD complex (Fig. 7), we speculate that elevated ex-
pression of ICAD-S may decrease the apoptotic propen-
sity of the nuclei. The apparently higher binding affinity of
ICAD-S to CAD as compared with that of ICAD would
further delay the caspase-dependent activation of the nu-
clease when the expression level of the alternatively
spliced ICAD is elevated (Gu et al., 1999). However, the
regulatory mechanisms, involved in the determination of
the steady state level of ICAD-S, are presently not known.
In conclusion, the experimental data presented in this
study indicate that two independent NLSs, identified in
ICAD and CAD, are necessary and sufficient to render
highly efficient, constitutive nuclear targeting of the ICAD/The Journal of Cell Biology, Volume 150, 2000 334
CAD heterodimer. These observations, together with the
nuclear accumulation of endogenous hICAD, and its re-
distribution on staurosporine-induced apoptosis in both
HeLa and caspase-3 transfected MCF7 cells, imply that
regulation of the apoptotic nuclease by the proteolytic
cleavage of ICAD takes place in the nucleus.
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